The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Case report: durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment Jin, Jing; Li, Junlong; Peng, Chao; More Jin, Jing; Li, Junlong; Peng, Chao; Chen, Jiajun; Xu, Gang; Pan, Shouhua Less Anti-Cancer Drugs. 34(6):797-802, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Successful osimertinib rechallenge after severe thrombocytopenia caused by osimertinib combined with sitagliptin: a case report Tan, Xinyuan; Chen, She; He, Liu; More Tan, Xinyuan; Chen, She; He, Liu; Huang, Minling; Zhang, Xiaoshan Less Anti-Cancer Drugs. 34(6):791-796, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Effect of Gubenyiliu formula II and its disassembled prescriptions on cell autophagy in breast cancer through PI3K/AKT/mTOR pathway Chen, Xiaojuan; Jin, Guoying; Luo, Hong; More Chen, Xiaojuan; Jin, Guoying; Luo, Hong; Zhou, Lifei Less Anti-Cancer Drugs. 34(6):725-734, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Stat3 shRNA delivery with folate receptor-modified multi-functionalized graphene oxide particles for combined infrared radiation and gene therapy in hepatocellular carcinoma Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; More Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; Xu, Libo; Sun, Jicheng; Liu, Yiran; Liu, Xiaorui; Kalvakolanu, Dhan V; Guo, Baofeng Less Anti-Cancer Drugs. 34(6):715-724, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
LncRNA ARAP1-AS1 targets miR-516b-5p/PDE5A axis to facilitate the progression of thyroid cancer Du, Qiuli; Huang, Lin; Guo, Wei Du, Qiuli; Huang, Lin; Guo, Wei Less Anti-Cancer Drugs. 34(6):735-746, July 2023. Abstract Abstract Favorite PDF Permissions Buy
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Panaxadiol targeting IL2 inducible T cell kinase promotes T cell immunity in radiotherapy Li, Jiuwei; Wang, Lu; Yu, Xiaodan; More Li, Jiuwei; Wang, Lu; Yu, Xiaodan; Guan, Yong; Wang, Xue Less Anti-Cancer Drugs. 34(6):705-714, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Stat3 shRNA delivery with folate receptor-modified multi-functionalized graphene oxide particles for combined infrared radiation and gene therapy in hepatocellular carcinoma Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; More Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; Xu, Libo; Sun, Jicheng; Liu, Yiran; Liu, Xiaorui; Kalvakolanu, Dhan V; Guo, Baofeng Less Anti-Cancer Drugs. 34(6):715-724, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
LncRNA ARAP1-AS1 targets miR-516b-5p/PDE5A axis to facilitate the progression of thyroid cancer Du, Qiuli; Huang, Lin; Guo, Wei Du, Qiuli; Huang, Lin; Guo, Wei Less Anti-Cancer Drugs. 34(6):735-746, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Successful osimertinib rechallenge after severe thrombocytopenia caused by osimertinib combined with sitagliptin: a case report Tan, Xinyuan; Chen, She; He, Liu; More Tan, Xinyuan; Chen, She; He, Liu; Huang, Minling; Zhang, Xiaoshan Less Anti-Cancer Drugs. 34(6):791-796, July 2023. Abstract Abstract Favorite PDF Permissions Buy
LncRNA ARAP1-AS1 targets miR-516b-5p/PDE5A axis to facilitate the progression of thyroid cancer Du, Qiuli; Huang, Lin; Guo, Wei Du, Qiuli; Huang, Lin; Guo, Wei Less Anti-Cancer Drugs. 34(6):735-746, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Successful osimertinib rechallenge after severe thrombocytopenia caused by osimertinib combined with sitagliptin: a case report Tan, Xinyuan; Chen, She; He, Liu; More Tan, Xinyuan; Chen, She; He, Liu; Huang, Minling; Zhang, Xiaoshan Less Anti-Cancer Drugs. 34(6):791-796, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Effect of Gubenyiliu formula II and its disassembled prescriptions on cell autophagy in breast cancer through PI3K/AKT/mTOR pathway Chen, Xiaojuan; Jin, Guoying; Luo, Hong; More Chen, Xiaojuan; Jin, Guoying; Luo, Hong; Zhou, Lifei Less Anti-Cancer Drugs. 34(6):725-734, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Case report: durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment Jin, Jing; Li, Junlong; Peng, Chao; More Jin, Jing; Li, Junlong; Peng, Chao; Chen, Jiajun; Xu, Gang; Pan, Shouhua Less Anti-Cancer Drugs. 34(6):797-802, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Stat3 shRNA delivery with folate receptor-modified multi-functionalized graphene oxide particles for combined infrared radiation and gene therapy in hepatocellular carcinoma Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; More Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; Xu, Libo; Sun, Jicheng; Liu, Yiran; Liu, Xiaorui; Kalvakolanu, Dhan V; Guo, Baofeng Less Anti-Cancer Drugs. 34(6):715-724, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Panaxadiol targeting IL2 inducible T cell kinase promotes T cell immunity in radiotherapy Li, Jiuwei; Wang, Lu; Yu, Xiaodan; More Li, Jiuwei; Wang, Lu; Yu, Xiaodan; Guan, Yong; Wang, Xue Less Anti-Cancer Drugs. 34(6):705-714, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Case report: durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment Jin, Jing; Li, Junlong; Peng, Chao; More Jin, Jing; Li, Junlong; Peng, Chao; Chen, Jiajun; Xu, Gang; Pan, Shouhua Less Anti-Cancer Drugs. 34(6):797-802, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Stat3 shRNA delivery with folate receptor-modified multi-functionalized graphene oxide particles for combined infrared radiation and gene therapy in hepatocellular carcinoma Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; More Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; Xu, Libo; Sun, Jicheng; Liu, Yiran; Liu, Xiaorui; Kalvakolanu, Dhan V; Guo, Baofeng Less Anti-Cancer Drugs. 34(6):715-724, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Stat3 shRNA delivery with folate receptor-modified multi-functionalized graphene oxide particles for combined infrared radiation and gene therapy in hepatocellular carcinoma Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; More Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; Xu, Libo; Sun, Jicheng; Liu, Yiran; Liu, Xiaorui; Kalvakolanu, Dhan V; Guo, Baofeng Less Anti-Cancer Drugs. 34(6):715-724, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Effect of Gubenyiliu formula II and its disassembled prescriptions on cell autophagy in breast cancer through PI3K/AKT/mTOR pathway Chen, Xiaojuan; Jin, Guoying; Luo, Hong; More Chen, Xiaojuan; Jin, Guoying; Luo, Hong; Zhou, Lifei Less Anti-Cancer Drugs. 34(6):725-734, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Case report: durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment Jin, Jing; Li, Junlong; Peng, Chao; More Jin, Jing; Li, Junlong; Peng, Chao; Chen, Jiajun; Xu, Gang; Pan, Shouhua Less Anti-Cancer Drugs. 34(6):797-802, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Case report: durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment Jin, Jing; Li, Junlong; Peng, Chao; More Jin, Jing; Li, Junlong; Peng, Chao; Chen, Jiajun; Xu, Gang; Pan, Shouhua Less Anti-Cancer Drugs. 34(6):797-802, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Neutrophil-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization combined with tyrosine kinase inhibitors plus programmed cell death ligand 1 antibody for unresectable hepatocellular carcinoma Zheng, Xin; Qian, Kun Zheng, Xin; Qian, Kun Less Anti-Cancer Drugs. 34(6):775-782, July 2023. Abstract Abstract Favorite PDF Permissions Buy
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Stat3 shRNA delivery with folate receptor-modified multi-functionalized graphene oxide particles for combined infrared radiation and gene therapy in hepatocellular carcinoma Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; More Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; Xu, Libo; Sun, Jicheng; Liu, Yiran; Liu, Xiaorui; Kalvakolanu, Dhan V; Guo, Baofeng Less Anti-Cancer Drugs. 34(6):715-724, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Successful osimertinib rechallenge after severe thrombocytopenia caused by osimertinib combined with sitagliptin: a case report Tan, Xinyuan; Chen, She; He, Liu; More Tan, Xinyuan; Chen, She; He, Liu; Huang, Minling; Zhang, Xiaoshan Less Anti-Cancer Drugs. 34(6):791-796, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Panaxadiol targeting IL2 inducible T cell kinase promotes T cell immunity in radiotherapy Li, Jiuwei; Wang, Lu; Yu, Xiaodan; More Li, Jiuwei; Wang, Lu; Yu, Xiaodan; Guan, Yong; Wang, Xue Less Anti-Cancer Drugs. 34(6):705-714, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Stat3 shRNA delivery with folate receptor-modified multi-functionalized graphene oxide particles for combined infrared radiation and gene therapy in hepatocellular carcinoma Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; More Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; Xu, Libo; Sun, Jicheng; Liu, Yiran; Liu, Xiaorui; Kalvakolanu, Dhan V; Guo, Baofeng Less Anti-Cancer Drugs. 34(6):715-724, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Panaxadiol targeting IL2 inducible T cell kinase promotes T cell immunity in radiotherapy Li, Jiuwei; Wang, Lu; Yu, Xiaodan; More Li, Jiuwei; Wang, Lu; Yu, Xiaodan; Guan, Yong; Wang, Xue Less Anti-Cancer Drugs. 34(6):705-714, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Case report: durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment Jin, Jing; Li, Junlong; Peng, Chao; More Jin, Jing; Li, Junlong; Peng, Chao; Chen, Jiajun; Xu, Gang; Pan, Shouhua Less Anti-Cancer Drugs. 34(6):797-802, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Stat3 shRNA delivery with folate receptor-modified multi-functionalized graphene oxide particles for combined infrared radiation and gene therapy in hepatocellular carcinoma Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; More Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; Xu, Libo; Sun, Jicheng; Liu, Yiran; Liu, Xiaorui; Kalvakolanu, Dhan V; Guo, Baofeng Less Anti-Cancer Drugs. 34(6):715-724, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; Kavgaci, Gozde; Aksun, Melek Seren; Erul, Enes; Yildirim, Hasan Cagri; Chalabiyev, Elvin; Cebroyilov, Cebrayil; Yildirim, Tolga; Dizdar, Omer; Aksoy, Sercan; Yalcin, Suayib; Kilickap, Saadettin; Erman, Mustafa; Arici, Mustafa Less Anti-Cancer Drugs. 34(6):783-790, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Panaxadiol targeting IL2 inducible T cell kinase promotes T cell immunity in radiotherapy Li, Jiuwei; Wang, Lu; Yu, Xiaodan; More Li, Jiuwei; Wang, Lu; Yu, Xiaodan; Guan, Yong; Wang, Xue Less Anti-Cancer Drugs. 34(6):705-714, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Stat3 shRNA delivery with folate receptor-modified multi-functionalized graphene oxide particles for combined infrared radiation and gene therapy in hepatocellular carcinoma Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; More Chen, Xuyang; Zhang, Ling; Wang, Xiaoqin; Xu, Libo; Sun, Jicheng; Liu, Yiran; Liu, Xiaorui; Kalvakolanu, Dhan V; Guo, Baofeng Less Anti-Cancer Drugs. 34(6):715-724, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Successful osimertinib rechallenge after severe thrombocytopenia caused by osimertinib combined with sitagliptin: a case report Tan, Xinyuan; Chen, She; He, Liu; More Tan, Xinyuan; Chen, She; He, Liu; Huang, Minling; Zhang, Xiaoshan Less Anti-Cancer Drugs. 34(6):791-796, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study Li, Yinjuan; Qi, Lu; Wang, Yu; More Li, Yinjuan; Qi, Lu; Wang, Yu; Zhao, Xia; Lv, Shuzhen; Feng, Yu; Liu, Chen; Li, Pu; Xiong, Bingjun; Guo, Yihui; Lv, Dapeng; Liu, Yongbo; Mao, Ting; Yuan, Keyu; Cheng, Xiaoqiang; Li, Yanping; Wang, Xinghe Less Anti-Cancer Drugs. 34(6):763-774, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
Neutrophil-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization combined with tyrosine kinase inhibitors plus programmed cell death ligand 1 antibody for unresectable hepatocellular carcinoma Zheng, Xin; Qian, Kun Zheng, Xin; Qian, Kun Less Anti-Cancer Drugs. 34(6):775-782, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Effect of Gubenyiliu formula II and its disassembled prescriptions on cell autophagy in breast cancer through PI3K/AKT/mTOR pathway Chen, Xiaojuan; Jin, Guoying; Luo, Hong; More Chen, Xiaojuan; Jin, Guoying; Luo, Hong; Zhou, Lifei Less Anti-Cancer Drugs. 34(6):725-734, July 2023. Abstract Abstract Favorite PDF Permissions Buy
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; More Lai, Jingjiang; Zhuo, Xiaoli; Yin, Ke; Jiang, Fengxian; Liu, Lei; Xu, Xiaoying; Liu, Hongjing; Wang, Jingliang; Zhao, Jing; Xu, Wei; Yang, Shuping; Guo, Honglin; Yuan, Xiaotian; Lin, Xiaoyan; Qi, Fanghua; Fu, Guobin Less Anti-Cancer Drugs. 34(6):747-762, July 2023. Abstract Abstract Favorite PDF Permissions Buy SDC
